Public health officials in the United Kingdom have identified a new recombinant strain of mpox in a traveller who recently returned from Asia. This discovery comes at a time when the spread of Clade Ib mpox has already prompted health authorities across Europe and the UK to remind at-risk groups to complete their mpox vaccination schedule. The latest finding reinforces that message, highlighting the importance of staying protected as the virus continues to evolve.
According to genomic sequencing, the newly detected mpox strain contains elements of Clade Ib and Clade IIb. Both types are circulating internationally, so a recombinant variant was not unexpected, the UK Health Security Agency (UKHSA) said. However, the agency emphasised that this mixed strain is a reminder of the virus’s ability to change over time, which makes surveillance, early detection, and timely vaccination essential.
What Is Mpox and How Does It Spread?
Mpox — previously known as monkeypox — is caused by the Orthopoxvirus family, the same group responsible for smallpox. Although mpox is generally milder than smallpox, it can still cause significant discomfort and, in some cases, severe illness.
Common symptoms appear within 5–21 days of exposure and may include:
- Fever and chills
- Headache and body pain
- Swollen lymph nodes
- Fatigue and general weakness
After these early signs, a rash with fluid-filled lesions typically appears. These lesions may occur on the hands, feet, face, chest, and sometimes the genital or anal region. The rash can last several weeks before fully healing.
Mpox spreads through:
- Direct skin-to-skin contact
- Contact with bodily fluids
- Prolonged face-to-face exposure to respiratory droplets
- Shared items such as bedding or clothing
Good hygiene, avoiding close contact with symptomatic individuals, and early medical consultation remain important prevention steps.
Understanding Clades: Why Clade Ib Matters
Mpox viruses are divided into two major clades: Clade I (including Ia and Ib) and Clade II. The global outbreak in 2022–2023 was largely caused by Clade IIb, which produces relatively milder disease.
Clade I viruses, however, have historically been associated with more severe illness and higher fatality rates, especially in regions with limited healthcare access. Clade Ib, a sub-group of Clade I, has recently appeared in cases reported in Europe and North America, mostly among individuals with a recent travel history. Because of these patterns, Clade Ib is considered important to monitor, even though the current risk to the general population in the UK remains low.
UK’s Public Health Response
The UKHSA is conducting enhanced monitoring, including:
- Genomic sequencing
- Contact tracing
- Clinical guidance to healthcare providers
Doctors have been asked to carefully evaluate patients with rashes following flu-like symptoms, particularly those with relevant travel history. The agency also clarified that Clade Ib mpox is no longer considered a high-consequence infectious disease (HCID) in the UK, reflecting improved clinical understanding and availability of medical tools to manage the virus.
Why Vaccination Remains Important
Vaccination continues to be one of the strongest tools for prevention, especially for at-risk groups such as:
- Individuals with multiple sexual partners
- Immunocompromised individuals
- People with known exposure to confirmed mpox cases
Recent recommendations urge eligible individuals to complete both doses of the mpox vaccine. As new variants emerge, vaccination can help reduce transmission, lessen the severity of symptoms, and lower the risk of complications.
Clade Ib mpox continues to circulate in several parts of Central and Eastern Africa, and thousands of cases have been reported since 2023. As international travel resumes at full scale, global health agencies stress the importance of awareness and timely prevention.
While Clade Ib remains a variant of concern, experts say that with proper surveillance, vaccination, and public awareness, the threat to general populations can be managed effectively.
